Abstract: Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.
Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
Type:
Grant
Filed:
March 19, 2021
Date of Patent:
June 6, 2023
Assignee:
ARCUS BIOSCIENCES, INC.
Inventors:
Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ui Sharif
Abstract: The present disclosure relates to therapeutic agents and combinations thereof (e.g., pharmaceutical compositions) for the treatment of a viral infection in a subject, tissue or cell.
Type:
Grant
Filed:
August 1, 2022
Date of Patent:
May 23, 2023
Assignee:
Flagship Pioneering Innovations VI, LLC
Inventors:
David Barry Kolesky, Michael Ka Chun Wong, Hok Hei Tam
Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
May 23, 2023
Assignee:
ABBOTT LABORATORIES
Inventors:
Rachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Type:
Grant
Filed:
October 22, 2020
Date of Patent:
May 9, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
Abstract: Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.
Type:
Grant
Filed:
June 16, 2022
Date of Patent:
May 2, 2023
Assignee:
VENATORX PHARMACEUTICALS, INC.
Inventors:
Christopher J. Burns, Glen Coburn, Guo-Hua Chu, Stephen M. Condon, Steven A. Boyd, Daniel C. Pevear
Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
April 25, 2023
Assignee:
ABBOTT LABORATORIES
Inventors:
Rachael Buck, Geralyn O. Duska-McEwen, Joseph P. Schaller
Abstract: Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.
Abstract: Oral formulations comprising a compound of Formula (I) and a chelating agent are provided, wherein compounds of Formula (I) have the structure: wherein, W, X, Y, Z, Ra, Rc, and each Rg are as defined herein. Also provided are methods of preparation, methods of use, and specific dosage forms.
Type:
Grant
Filed:
March 5, 2021
Date of Patent:
April 25, 2023
Assignee:
ARCUS BIOSCIENCES, INC.
Inventors:
Kenneth Victor Lawson, Manmohan Reddy Leleti, Jay Patrick Powers
Abstract: The invention relates generally to a pharmacological therapy for a human genetic diseases, specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxyribonucleoside monophosphate, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine monophosphate (dTMP) or deoxycytidine monophosphate (dCMP), or mixtures thereof. This molecular bypass approach is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
Abstract: This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.
Type:
Grant
Filed:
July 6, 2020
Date of Patent:
April 18, 2023
Assignee:
Emory University
Inventors:
George R. Painter, David Guthrie, Gregory R. Bluemling, Michael G. Natchus
Abstract: Provided herein are efficient and scalable methods for the synthesis of nicotinamide riboside from riboside triacetate. Also provided are compositions comprising nicotinamide riboside, and therapeutic methods employing nicotinamide riboside.
Type:
Grant
Filed:
June 29, 2018
Date of Patent:
April 18, 2023
Assignee:
Elysium Health, Inc.
Inventors:
Eric Marcotulli, Dan Alminana, Ryan Dellinger, Mark Morris, Rajesh Thamatam
Abstract: A new isoform of 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3/4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate (Remdesivir) having increased water solubility is disclosed, along with methods for making the same. Also disclosed are solid and liquid pharmaceutical compositions suitable for treating viral infections such as Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, or Paramyxoviridae viral infections which contain an effective amount of Remdesivir prepared according to the inventive method and the use of those compositions for treating such viral infections.
Abstract: Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of inhibiting or reducing viral replication or the production of viral RNA or DNA or viral protein using such Compounds, and methods for treating viral infections, such as an RNA virus belonging to the family Coronaviridae, involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
Abstract: The present invention includes Uttroside B compositions and method for the treatment of hepatocellular carcinoma. Chemotherapeutic options for liver cancer are limited and the prognosis of HCC patients remains dismal. Sorafenib, is the only drug currently available for the treatment of hepatocellular carcinoma.
Type:
Grant
Filed:
January 29, 2021
Date of Patent:
March 21, 2023
Assignee:
RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY, AN AUTONOMOUS INSTITUTE UNDER THE DEPARTMENT OF BIOTECHNOLOGY. GOVERNMENT OF INDIA
Abstract: Described herein is an intronic recognition element for splicing modifier (iREMS) that can be recognized by a small molecule splicing modifier compound of Formula (I) provided herein or a form thereof, wherein W, X, A and B are as defined herein. In one aspect, methods for modifying RNA splicing to modulate the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene that contains an intronic REMS is modified utilizing a splicing modifier compound of Formula (I), are described herein. In another aspect, methods for modifying RNA splicing to modulate the amount of an RNA transcript or protein product encoded by a gene, wherein a precursor RNA transcript transcribed from the gene is modified to comprise an intronic REMS utilizing a splicing modifier compound of Formula (I), are described herein.
Type:
Grant
Filed:
June 13, 2018
Date of Patent:
March 21, 2023
Assignee:
PTC Therapeutics, Inc.
Inventors:
Anuradha Bhattacharyya, Amal Dakka, Kerstin Effenberger, Vijayalakshmi Gabbeta, Minakshi B. Jani, Wencheng Li, Nikolai Naryshkin, Christopher Trotta, Kari Wiedinger
Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
Type:
Grant
Filed:
December 9, 2020
Date of Patent:
March 14, 2023
Assignee:
University of Kentucky Research Foundation
Abstract: The present invention provides a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. It also provides a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate.
Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.
Type:
Grant
Filed:
April 22, 2022
Date of Patent:
March 14, 2023
Assignee:
RESURGE THERAPEUTICS INC.
Inventors:
Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
Abstract: This disclosure provides electrochemically-cleavable linkers with cleavage potentials that are less than the redox potential of the solvent in which the linkers are used. In some applications, the solvent may be water or an aqueous buffer solution. The linkers may be used to link a nucleotide to a bound group. The linkers include a cleavable group which may be one of a methoxybenzyl alcohol, an ester, a propargyl thioether, or a trichloroethyl ether. The linkers may be cleaved in solvent by generating an electrode potential that is less than the redox potential of the solvent. In some implementations, an electrode array may be used to generate localized electrode potentials which selectively cleave linkers bound to the activated electrode. Uses for the linkers include attachment of blocking groups to nucleotides in enzymatic oligonucleotide synthesis.